not sure why IMGN is bid at 20.5, cc is not great other than they have a lot of opportunities, progress is still slow. Charlie is adding some value on the call. I wish they had John Lambert on these calls. I was glad to hear Greg say they are not planning to monetize Kadcyla. 901 is moving at a snail's pace. Some DLT's mentioned, on some of the dose finding studies, reversable, blurred vision, but probably nothing unusual.
I don't think analysts will be pounding the table at $20+ based on this call. However, relative to SGEN, IMGN still seems inexpensive, or fairly valued at most. Lots of analyst participation on the call.